UCB licenses ATG-201, Antengene’s masked CD19 T-cell engager, for global autoimmune disease development. $80M upfront, up to $1.1B milestones. Phase 1 trials set for 2026 in China, Australia.
Written By: Marka Sheshi, PharmD
Reviewed By: Pharmacally Editorial Team
UCB, a leading global biopharmaceutical company, has inked a landmark deal with Antengene Corporation Limited, granting UCB worldwide exclusive rights to develop, manufacture, and commercialize ATG-201 a promising CD19-targeting bispecific T-cell engager (TCE) designed for B-cell-driven diseases like autoimmune disorders.
TCEs work by harnessing T cells to selectively eliminate harmful B cells expressing CD19, offering precise immune-mediated action with potential for durable responses. ATG-201 leverages Antengene’s innovative AnTenGager™ platform, featuring steric masking of the CD3-binding arm to enhance tolerability, bivalent CD19 binding for potent depletion, and a proprietary CD3 sequence to minimize cytokine release syndrome (CRS) risks.
Antengene plans to file clinical trial applications for ATG-201 in China and Australia during Q1 2026, conducting first-in-human Phase 1 studies before handing over further development to UCB.
The partnership underscores UCB’s inorganic innovation strategy. “Access to Antengene’s cutting-edge T-cell engager platform enhances our ambition to lead in immunology,” said Alistair Henry, UCB’s Chief Scientific Officer. “It complements our monoclonal antibody expertise and brings us into the advancing field of bispecific TCEs.”
Antengene’s Founder, Chairman, and CEO Dr. Jay Mei added, “Combining our platform with UCB’s immunology prowess will accelerate ATG-201 globally for autoimmune diseases.”
Financially, Antengene receives $80 million in upfront and near-term milestones, plus up to $1.1 billion in development and commercial milestones, alongside tiered royalties on net sales.
This deal positions ATG-201 as a scalable contender in immunology, potentially disrupting treatment paradigms for B-cell mediated conditions.
References
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody, 03 March 2026, UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody | UCB
About Writer
Marka Sheshi | Doctor of Pharmacy
Driven by a deep commitment to clinical excellence, research integrity, and impactful medical writing. With a strong foundation in pharmacotherapy and patient safety, specializes in transforming complex scientific evidence into authoritative, publication-ready content. Passionate about advancing healthcare through precise, evidence-based communication that informs practice, strengthens research visibility, and improves patient outcomes.